Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and pharmacokinetics of ceftobiprole in neonates and young infants with late-onset sepsis
2022-001837-35Phase 3Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Aug 2022
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ceftobiprole medocaril in late-onset neonatal sepsis (LONS) and bacterial disease, sponsored by Basilea Pharmaceutica. Primary endpoint: Primary safety and tolerability endpoint. Started Aug 2022; status: completed.
02
Drugs
ceftobiprole medocaril
03
Conditions
late-onset neonatal sepsis (LONS)bacterial disease
Beyond the preview
Go deeper on 2022-001837-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001837-35.